Clinical Trial Update: First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov record reports a Phase 2 trial of first-line osimertinib for patients with EGFR-mutated non-small cell lung cancer; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Vestre Viken Hospital Trust | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING